The use of organ sparing strategies to treat penile cancer (PC) is currently supported by evidence that has indicated the safety, efficacy and benefit of this surgery. However, radical penectomy still represents up to 15-20% of primary tumor treatments in PC patients. The aim of the study was to evaluate efficacy in terms of overall survival (OS) and disease-free survival (DFS) of radical penectomy in PC patients.

Background: The use of organ sparing strategies to treat penile cancer (PC) is currently supported by evidence that has indicated the safety, efficacy and benefit of this surgery. However, radical penectomy still represents up to 15-20% of primary tumor treatments in PC patients. The aim of the study was to evaluate efficacy in terms of overall survival (OS) and disease-free survival (DFS) of radical penectomy in PC patients. Methods: Data from a retrospective multicenter study (PEnile Cancer ADherence study, PECAD Study) on PC patients treated at 13 European and American urological centers (Hospital “Sant'Andrea”, Sapienza University, Roma, Italy; “G.D'Annunzio” University, Chieti and ASL 2 Abruzzo, Hospital “S. Pio da Pietrelcina”, Vasto, Italy; Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA; Hospital of Budapest, Hungary; Department of Emergency and Organ Transplantation, Urology and Andrology Unit II, University of Bari, Italy; Hospital “Spedali Civili”, Brescia, Italy; Istituto Europeo di Oncologia, University of Milan, Milan, Italy; University of Modena & Reggio Emilia, Modena, Italy; Hospital Universitario La Paz, Madrid, Spain; Ceara Cancer Institute, Fortaleza, Brazil; Virginia Commonwealth University, Richmond, VA, USA; Aristotle University of Thessaloniki, Thessaloniki, Greece; Maria Skłodowska-Curie Memorial Cancer Center, Warsaw, Poland) between 2010 and 2016 were used. Medical records of patients who specifically underwent radical penectomy were reviewed to identify main clinical and pathological variables. Kaplan-Meier method was used to estimate 1- and 5-year OS and DFS. Results: Of the entire cohort of 425 patients, 72 patients (16.9%) treated with radical penectomy were extracted and were considered for the analysis. The median age was 64.5 (IQR, 57.5-73.2) years. Of all, 41 (56.9%) patients had pT3/pT4 and 31 (43.1%) pT1/pT2. Moreover, 36 (50.0%) were classified as pN1-3 and 5 (6.9%) M1. Furthermore, 61 (84.7%) had a high grade (G2-G3) with 6 (8.3%) positive surgical margins. The 1- and 5-year OS rates were respectively 73.3% and 59.9%, while the 1- and 5-year DFS rates were respectively 67.3% and 35.1%. Conclusions: PC is an aggressive cancer particularly in more advanced stage. Overall, more than a third of patients do not survive at 5 years and more than 60% report a disease recurrence, despite the use of a radical treatment.

Radical penectomy, a compromise for life: results from the PECAD study / Ghahhari, Jamil; Marchioni, Michele; Spiess, Philippe E; Chipollini, Juan J; Nyirády, Peter; Varga, Judith; Ditonno, Pasquale; Boccasile, Stefano; Primiceri, Giulia; De Nunzio, Cosimo; Tema, Giorgia; Tubaro, Andrea; Veccia, Alessandro; Antonelli, Alessandro; Musi, Gennaro; De Cobelli, Ottavio; Conti, Andrea; Puliatti, Stefano; Micali, Salvatore; Álvarez-Maestro, Mario; Quesada Olarte, José; Diogenes, Erico; Lima, Marcos Venicio Alves; Tracey, Andrew; Guruli, Georgi; Autorino, Riccardo; Sountoulides, Petros; Sosnowski, Roman; Schips, Luigi; Cindolo, Luca. - In: TRANSLATIONAL ANDROLOGY AND UROLOGY. - ISSN 2223-4691. - 9:3(2020), pp. 1306-1313. [10.21037/tau.2020.04.04]

Radical penectomy, a compromise for life: results from the PECAD study

Puliatti, Stefano;Micali, Salvatore;
2020

Abstract

Background: The use of organ sparing strategies to treat penile cancer (PC) is currently supported by evidence that has indicated the safety, efficacy and benefit of this surgery. However, radical penectomy still represents up to 15-20% of primary tumor treatments in PC patients. The aim of the study was to evaluate efficacy in terms of overall survival (OS) and disease-free survival (DFS) of radical penectomy in PC patients. Methods: Data from a retrospective multicenter study (PEnile Cancer ADherence study, PECAD Study) on PC patients treated at 13 European and American urological centers (Hospital “Sant'Andrea”, Sapienza University, Roma, Italy; “G.D'Annunzio” University, Chieti and ASL 2 Abruzzo, Hospital “S. Pio da Pietrelcina”, Vasto, Italy; Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA; Hospital of Budapest, Hungary; Department of Emergency and Organ Transplantation, Urology and Andrology Unit II, University of Bari, Italy; Hospital “Spedali Civili”, Brescia, Italy; Istituto Europeo di Oncologia, University of Milan, Milan, Italy; University of Modena & Reggio Emilia, Modena, Italy; Hospital Universitario La Paz, Madrid, Spain; Ceara Cancer Institute, Fortaleza, Brazil; Virginia Commonwealth University, Richmond, VA, USA; Aristotle University of Thessaloniki, Thessaloniki, Greece; Maria Skłodowska-Curie Memorial Cancer Center, Warsaw, Poland) between 2010 and 2016 were used. Medical records of patients who specifically underwent radical penectomy were reviewed to identify main clinical and pathological variables. Kaplan-Meier method was used to estimate 1- and 5-year OS and DFS. Results: Of the entire cohort of 425 patients, 72 patients (16.9%) treated with radical penectomy were extracted and were considered for the analysis. The median age was 64.5 (IQR, 57.5-73.2) years. Of all, 41 (56.9%) patients had pT3/pT4 and 31 (43.1%) pT1/pT2. Moreover, 36 (50.0%) were classified as pN1-3 and 5 (6.9%) M1. Furthermore, 61 (84.7%) had a high grade (G2-G3) with 6 (8.3%) positive surgical margins. The 1- and 5-year OS rates were respectively 73.3% and 59.9%, while the 1- and 5-year DFS rates were respectively 67.3% and 35.1%. Conclusions: PC is an aggressive cancer particularly in more advanced stage. Overall, more than a third of patients do not survive at 5 years and more than 60% report a disease recurrence, despite the use of a radical treatment.
2020
4-apr-2020
9
3
1306
1313
Radical penectomy, a compromise for life: results from the PECAD study / Ghahhari, Jamil; Marchioni, Michele; Spiess, Philippe E; Chipollini, Juan J; Nyirády, Peter; Varga, Judith; Ditonno, Pasquale; Boccasile, Stefano; Primiceri, Giulia; De Nunzio, Cosimo; Tema, Giorgia; Tubaro, Andrea; Veccia, Alessandro; Antonelli, Alessandro; Musi, Gennaro; De Cobelli, Ottavio; Conti, Andrea; Puliatti, Stefano; Micali, Salvatore; Álvarez-Maestro, Mario; Quesada Olarte, José; Diogenes, Erico; Lima, Marcos Venicio Alves; Tracey, Andrew; Guruli, Georgi; Autorino, Riccardo; Sountoulides, Petros; Sosnowski, Roman; Schips, Luigi; Cindolo, Luca. - In: TRANSLATIONAL ANDROLOGY AND UROLOGY. - ISSN 2223-4691. - 9:3(2020), pp. 1306-1313. [10.21037/tau.2020.04.04]
Ghahhari, Jamil; Marchioni, Michele; Spiess, Philippe E; Chipollini, Juan J; Nyirády, Peter; Varga, Judith; Ditonno, Pasquale; Boccasile, Stefano; Pri...espandi
File in questo prodotto:
File Dimensione Formato  
Radical penectomy, a compromise for life results from the PECAD study.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 431.31 kB
Formato Adobe PDF
431.31 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1248915
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 8
social impact